Direct supply of validated testing cohorts, active ingredients, and OEM/ODM trial batches managed end-to-end under strict cGMP protocols.
An in-depth assessment of regulatory agility, patient-cohort density, multi-omics botanical characterization, and cost efficiencies driving international Investigational New Drug (IND) development.
Since the accession of China's NMPA to the International Council for Harmonisation (ICH) in 2017, early-stage trial guidelines mirror FDA and EMA technical baselines. MedGence ensures that all protocol architectures, electronic data capture (EDC) systems, and clinical quality assurance procedures meet global eCTD Module 4 and 5 submission standards for unhindered worldwide cross-acceptance.
Phase 1 trials demand meticulously screened, homogenous cohorts of healthy volunteers and precise micro-stratified patient segments for oncology and metabolic indications. China’s centralized tertiary medical ecosystem and our network of certified Phase 1 clinical trial units dramatically condense First-Subject-In (FSI) to Last-Subject-Out (LSO) timelines by 40% to 60% compared to Western benchmarks.
Eliminate trial derailment risks resulting from Chemistry, Manufacturing, and Controls (CMC) bottlenecks. We directly integrate high-potency active ingredient extraction, chromatographic fingerprint standardization, and trial dosage batching (capsules, oral liquids, tablets) directly into the clinical site workflow under strict non-disclosure protections.
Combining classical ethnobotanical pharmacology with cutting-edge analytical chemistry and controlled Phase 1 human pharmacokinetic evaluation.
Quantitative fractionation and multi-target isolation of saponins, polysaccharides, polyphenols, and alkaloids to discover viable chemical entities.
Evaluating raw-material chemical divergence based on seasonal collection, geographical altitude, soil chemistry, and plant morphology.
Development and validation of robust HPLC, HPTLC, GC-MS, and LC-MS/MS fingerprinting assay methodologies complying with Pharmacopeial protocols.
Pilot-to-commercial scale purification, counter-current extraction, and spray drying optimization to secure high batch yield and reproducible purity.
Mitigating active compound oxidation, solubility barriers, and bioavailability loss across solid dosage, oral suspension, and softgel platforms.
Comprehensive toxicity profiling: LD50, acute non-rodent exposures, sub-chronic toxicity, hERG cardiac assays, and in vivo genotoxicity dossiers.
Targeted receptor-binding assays, kinase activity assays, antiviral cytopathic inhibition assays, and metabolic pathway target profiling.
Validated disease animal models for immunomodulation, oncology xenografts, glycemic index normalization, and central nervous system dynamics.
First-in-Human (FIH), Single Ascending Dose (SAD), Multiple Ascending Dose (MAD), food-effect, and early biomarker response studies under ICH-GCP.
Translating historical medical formulations into standardized molecular mechanisms, backed by hospital preparation regulatory authorizations.
OEM cGMP extraction suites generating pharmaceutical-grade active fractions in dried powders, vacuum pastes, and supercritical volatile oils.
Over-encapsulated matching placebos, blinding verifications, clinical-label packaging, and refrigerated distribution direct to GCP trial sites.
Strategic risk mitigation designed specifically for international biotechnology procurement managers and cross-border clinical trial sponsors.
Navigating Chinese regulatory landscapes requires meticulous HGRAC protocol structuring. MedGence’s local regulatory affairs group prepares, manages, and secures biosecurity reviews and cross-border data export authorizations, ensuring multinational trial sponsors encounter zero compliance delays.
Our research headquarters in Changsha, Hunan, sits at the geographical heart of China’s richest botanical producing regions. We enforce strict Good Agricultural and Collection Practices (GACP), auditing pesticide residues, heavy metals, and mycotoxins to ensure clinical batches never risk contamination.
International clients preserve their proprietary molecules and formulation trade secrets through our siloed contract synthesis architecture. We operate on strict firewall protocols where chemical structures, analytical methodologies, and clinical data packages remain the sole, uncompromised intellectual property of the sponsor.
How international pharmaceutical sponsors optimize development expenditures across dietary supplement trials and prescription drug discovery.
Consumer health brands face intensifying regulatory scrutiny globally regarding functional efficacy claims. We perform rigorous human pilot pharmacokinetic assays, bioavailability evaluations, and double-blind, randomized placebos-controlled trials to validate label claims for global retail compliance.
Advancing botanical entities through modern drug discovery pipelines demands rigorous chemical consistency. We generate comprehensive dossiers including HPTLC/HPLC fingerprints, cell assays, animal pharmacology, and First-in-Human clinical data supporting US FDA Botanical IND applications.
High-end cosmetic brands require empirical safety and clinical verification for botanical actives. Our Phase 1 units execute human repeat insult patch tests (HRIPT), transepidermal water loss (TEWL) analytics, and barrier repair studies under dermatologist-supervised protocols.
Key technical, legal, and operational answers for pharmaceutical development directors evaluating Chinese manufacturing and trial execution.
Our long-term research collaborations and CDMO partnerships span premier academic medical centers and industrial leaders.
Tongrentang Group
CR Sanjiu
Sunflower Pharma
Livzon Pharma
Dihon Pharma
Golden Throat
Yangtzi River Pharma
Humanwell Group
Apeloa Pharma
Shuguang Hospital
2nd Xiangya Hospital
Hunan University HospitalExplore contract manufacturing options and study services available for worldwide clinical and commercial deployment.
